T.R. Pedersen
19 works · 8,469 citations · h-index 1
Top works
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
- 624 THE TRP719ARG VARIANT OF KIF6 AND CARDIOVASCULAR OUTCOMES IN STATIN-TREATED CORONARY STABLE PATIENTS OF THE TNT AND IDEAL PROSPECTIVE STUDIES
- Tu-W20:1 Lipid guidelines - one for all?
- Mo-S7:5 Cardiovascular outcomes studies to seas the future
- LB-PO-858 APOB/APOA-1 IS MORE PREDICTIVE OF AMI IN RHEUMATOID ARTHRITIS THAN LDL-C OR NHDL-C/HDL-C IN THE AMORIS STUDY
- Evolocumab and Outcomes in Patients With Peripheral Artery Disease
- LB-PO-859 LIPID LEVELS AS PREDICTORS OF DEVELOPMENT OF RHEUMATOID ARTHRITIS IN THE AMORIS POPULATION
- PO23-735 RISK REDUCTION WITH INTENSIVE VERSUS STANDARD STATIN THERAPY IN ACUTE CORONARY SYNDROME: IDEAL TRIAL
- 788 EFFECT OF INTENSIVE LIPID LOWERING ON CARDIOVASCULAR OUTCOME IN PATIENTS WITH AND WITHOUT INFLAMMATORY JOINT DISEASE
- Proceedings of the 2nd International Merck Symposium on HDL-C Raising - Bridging the gap in cardiovascular risk reduction: A call to action - Barcelona, 14-15 October, 2005 - Guest editorial
- 785 PREDICTION OF CARDIOVASCULAR EVENTS IN PATIENTS WITH ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS
- Tu-W29:7 Effect of differential treatment adherence on outcome in the ideal trial
- Total homocysteine levels predicts major coronary events and mortality in simvastatin treated patients of 4S
- PO23-743 EFFECT OF INTENSIVE VERSUS STANDARD STATIN THERAPY IN YOUNGER AND OLDER CORONARY HEART DISEASE (CHD) PATIENTS IN THE IDEAL TRIAL
- LB-OR-2 HIGH HDL-C AND CHD RISK IN STATIN-TREATED CHD PATIENTS: ANALYSIS OF INCREMENTAL DECREASE IN ENDPOINTS THROUGH AGGRESSIVE LIPID-LOWERING (IDEAL) TRIAL
- LDL CHOLESTEROL GOAL ATTAINMENTS IN THE IDEAL STUDY
- PCV46 ECONOMIC EVALUATION OF 80 MG ATORVASTATIN COMPARED TO 20-40 MG SIMVASTATIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES
- PO23-741 ON-TREATMENT HDL-C LEVELS AND RISK OF MAJOR CARDIOVASCULAR EVENTS IN THE IDEAL TRIAL
- INTENSIVE ATORVASTATIN THERAPY REDUCES RISK OF CARDIOVASCULAR EVENTS BEYOND THE FIRST EVENT IN PATIENTS WITH MULTIPLE EVENTS